NCT00514696View on ClinicalTrials.gov

Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

GCS-100

GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle

Trial Locations (8)

23502

Virginia Oncology Associates, Norfolk

32789

Cancer Centers of Florida, Winter Park

45409

Dayton Oncology & Hematology, Kettering

46219

Central Indiana Cancer Centers, Indianapolis

75702

Tyler Cancer Center, Tyler

80218

Rocky Mountain Cancer Centers, Denver

98684

Northwest Cancer Specialists - Vancouver Cancer Center, Vancouver

98902

Yakima Cancer Center, Yakima

Sponsors
All Listed Sponsors
lead

La Jolla Pharmaceutical Company

INDUSTRY

NCT00514696 - Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter